Skip to main content
Premium Trial:

Request an Annual Quote

Helicos' Shares Soar Day After Publication; CFO to Depart

NEW YORK (GenomeWeb News) – Shares of Helicos BioSciences closed up 40 percent on Tuesday, a day after the firm's technology was used to sequence the genome of one of its co-founders.

The paper, published in Nature Biotechnology, detailed how Stephen Quake, a Stanford University bioengineer and Helicos co-founder, sequenced his own genome using a single Heliscope machine and four data collection runs. He was able to achieve this feat in about four weeks at a cost of around $48,000 in sequencing reagents.

Investors reacted positively to the news, sending Helicos' shares as high as $1.70 during Tuesday's trading session, before closing at $1.01.

Helicos also disclosed Tuesday that its CFO, Stephen Hall, will be leaving the firm. Helicos said in a filing with the US Securities and Exchange Commission that Hall will leave that role after the firm files its form 10-Q, which is expected to occur this Friday, Aug. 14.

The Scan

Science Confidence Boost

The New York Times reports that a new poll finds trust in science and scientists has increased with the COVID-19 pandemic.

Appeal and Funds

Some grant applications denied funding due to an Australian Research Council rule change have now been funded following an appeal, the Guardian reports.

Surveillance for Variants

Vox writes that the detection of the Omicron SARS-CoV-2 variant highlights the need for improved viral genomic surveillance.

Nature Papers Examine Taxonomic Gaps in Plant Sequencing, SARS-CoV-2-Human Interactome

In Nature this week: plant genome sequencing dominated by affluent countries, and more.